Closely held Illuminate Health is leveraging a technology-enabled continuous medication management platform to help patients optimize medications at home to improve treatment adherence and reduce hospitalizations.
Annovis Bio (NYSE:ANVS) is developing a lead drug candidate, ANVS401, to inhibit more than one neurotoxic protein, improving the information highway of nerve cells, known as axonal transport, for the treatment of...
Rani Therapeutics (NASDAQ:RANI) is developing a disruptive technology to solve the problem of converting biologic injectable drugs, including antibodies, peptides and proteins, into oral therapies with its RaniPill that...
As a co-founder and CEO of closely held Cellares, which is pioneering an automated approach to cell therapy manufacturing, Fabian Gerlinghaus, an aerospace engineer by training, made the switch to biotech eight years...
As a research assistant professor at the Department of Pharmacology at the University of Washington, Dr. Ben Land, Ph.D. is broadly interested in how cannabinoids and opioids mediate pain and reward. But in a...
NervGen Pharma (TSX-V:NGEN; OTCQX:NGENF) is developing a new class of drugs that repairs damage to the nervous system and restores motor, sensory and cognitive function to diseases where there are currently no approved...
Recently launched Lanier Biotherapeutics is developing specialty biologic treatments for indications in multifunctional retina, dermatology and Type 2 inflammation diseases.
Even though a number of antiviral medications are in use to treat chronic hepatitis B virus (HBV) infections, Aligos Therapeutics (NASDAQ:ALGS) is going one step further with a portfolio of drug candidates in clinical...
After a failed Phase 3 trial in August 2020 with its CaPre lead drug candidate for patients with severe hypertriglyceridemia, Acasti Pharma (NASDAQ, TSXV:ACST) has transitioned into the rare and orphan disease sector...